Preferred Label : Erdafitinib;
NCIt synonyms : 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-;
NCIt definition : An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with
potential antineoplastic activity. Upon oral administration, erdafitinib binds to
and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction
pathways and thus the inhibition of tumor cell proliferation and tumor cell death
in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is
a receptor tyrosine kinase essential to tumor cell proliferation, differentiation
and survival.;
UNII : 890E37NHMV;
InChIKey : OLAHOMJCDNXHFI-UHFFFAOYSA-N;
CAS number : 1346242-81-6;
Drug name : Balversa;
Molecule name : JNJ-42756493; JNJ 42756493;
Codes from synonyms : 196;
Origin ID : C103273;
UMLS CUI : C4519323;
Currated CISMeF NLP mapping
Manual BTNT mappings - CISMeF
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
concept_is_in_subset
has_target
is_component_of_chemotherapy_regimen
https://www.has-sante.fr/jcms/p_3506762/fr/balversa-erdafitinib-carcinome-urothelial
2024
false
false
false
France
erdafitinib
administration, oral
Product containing only erdafitinib in oral dose form (medicinal product form)
evaluation of the transparency committee
erdafitinib
erdafitinib
Erdafitinib
---